TY - JOUR
T1 - Characterization of a “low-risk” cohort of grade group 2 prostate cancer patients
T2 - Results from the Shared Equal Access Regional Cancer Hospital database
AU - McGinley, Kathleen F.
AU - Sun, Xizi
AU - Howard, Lauren E.
AU - Aronson, William J.
AU - Terris, Martha K.
AU - Kane, Christopher J.
AU - Amling, Christopher L.
AU - Cooperberg, Matthew R.
AU - Freedland, Stephen J.
N1 - Funding Information:
Research support was received from the NIH/NCI under award number P50CA09231 (William J Aronson) and NIH K24 CA160653 (Stephen J Freedland).
Publisher Copyright:
© 2017 The Japanese Urological Association
PY - 2017/8
Y1 - 2017/8
N2 - Objectives: To examine if there is a subset of men with grade group 2 prostate cancer who could be potential candidates for active surveillance. Methods: We used the Shared Equal Access Regional Cancer Hospital database to identify 776 men undergoing radical prostatectomy from 2006 to 2015 with >8 biopsy cores obtained and complete information. We compared men who fulfilled low-risk disease criteria (clinical stage T1c/T2a; grade group 1; prostate-specific antigen ≤10 ng/mL) with the exception of grade group 2 versus men who met all three low-risk criteria. Logistic regression was used to test the association between grade group and radical prostatectomy pathological features. Biochemical recurrence was examined using Cox models. To examine whether there was a subset of men with low-volume grade group 2 with comparable outcomes to low-risk men, we repeated all analyses limiting the percentage of positive cores in the grade group 2 group to ≤33%, and positive cores to ≤4, ≤3 or ≤2. Results: Grade group 2 low-risk men had increased risk of pathological grade group 3 or higher (P < 0.001), extraprostatic extension (P < 0.001), seminal vesicle invasion (P < 0.001) and higher risk of biochemical recurrence (hazard ratio = 1.76, P = 0.006). Using increasingly strict definitions of low-volume disease, at ≤2 positive cores there was no difference in adverse pathology between groups (all P > 0.2), except higher pathological grade group (P = 0.006). Biochemical recurrence was similar in men in grade group 1 and grade group 2 (hazard ratio = 1.24; P = 0.529). Conclusions: Among men with prostate-specific antigen ≤10 ng/mL and clinical stage T1c/T2a, those in grade group 2 with ≤2 total positive cores have similar rates of adverse pathology and biochemical recurrence as men with grade group 1.
AB - Objectives: To examine if there is a subset of men with grade group 2 prostate cancer who could be potential candidates for active surveillance. Methods: We used the Shared Equal Access Regional Cancer Hospital database to identify 776 men undergoing radical prostatectomy from 2006 to 2015 with >8 biopsy cores obtained and complete information. We compared men who fulfilled low-risk disease criteria (clinical stage T1c/T2a; grade group 1; prostate-specific antigen ≤10 ng/mL) with the exception of grade group 2 versus men who met all three low-risk criteria. Logistic regression was used to test the association between grade group and radical prostatectomy pathological features. Biochemical recurrence was examined using Cox models. To examine whether there was a subset of men with low-volume grade group 2 with comparable outcomes to low-risk men, we repeated all analyses limiting the percentage of positive cores in the grade group 2 group to ≤33%, and positive cores to ≤4, ≤3 or ≤2. Results: Grade group 2 low-risk men had increased risk of pathological grade group 3 or higher (P < 0.001), extraprostatic extension (P < 0.001), seminal vesicle invasion (P < 0.001) and higher risk of biochemical recurrence (hazard ratio = 1.76, P = 0.006). Using increasingly strict definitions of low-volume disease, at ≤2 positive cores there was no difference in adverse pathology between groups (all P > 0.2), except higher pathological grade group (P = 0.006). Biochemical recurrence was similar in men in grade group 1 and grade group 2 (hazard ratio = 1.24; P = 0.529). Conclusions: Among men with prostate-specific antigen ≤10 ng/mL and clinical stage T1c/T2a, those in grade group 2 with ≤2 total positive cores have similar rates of adverse pathology and biochemical recurrence as men with grade group 1.
KW - biopsy
KW - neoplasm grading
KW - neoplasm recurrence
KW - prostate cancer
KW - prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=85020199637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020199637&partnerID=8YFLogxK
U2 - 10.1111/iju.13387
DO - 10.1111/iju.13387
M3 - Article
C2 - 28589550
AN - SCOPUS:85020199637
SN - 0919-8172
VL - 24
SP - 611
EP - 617
JO - International Journal of Urology
JF - International Journal of Urology
IS - 8
ER -